Inventurus Knowledge Solutions Ltd
Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]
- Market Cap ₹ 22,817 Cr.
- Current Price ₹ 1,329
- High / Low ₹ 1,876 / 1,226
- Stock P/E 34.4
- Book Value ₹ 131
- Dividend Yield 0.00 %
- ROCE 27.2 %
- ROE 32.9 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 28.7% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 37.0%
Cons
- Stock is trading at 10.2 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 529 | 553 | 764 | 1,031 | 1,818 | 2,664 | 3,060 | |
| 367 | 348 | 466 | 639 | 1,297 | 1,893 | 2,047 | |
| Operating Profit | 162 | 205 | 298 | 392 | 521 | 771 | 1,013 |
| OPM % | 31% | 37% | 39% | 38% | 29% | 29% | 33% |
| 31 | 16 | 1 | -2 | 40 | 39 | 16 | |
| Interest | 7 | 8 | 7 | 6 | 61 | 91 | 79 |
| Depreciation | 40 | 30 | 23 | 25 | 59 | 113 | 118 |
| Profit before tax | 145 | 183 | 269 | 359 | 442 | 606 | 832 |
| Tax % | 5% | 9% | 13% | 15% | 16% | 20% | |
| 137 | 165 | 233 | 305 | 370 | 486 | 663 | |
| EPS in Rs | 166.73 | 200.10 | 13.61 | 17.86 | 21.68 | 28.33 | 38.65 |
| Dividend Payout % | 0% | 12% | 393% | 55% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 38% |
| 3 Years: | 52% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 25% |
| TTM: | 65% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 39% |
| 3 Years: | 37% |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 275 | 449 | 630 | 812 | 1,141 | 1,773 | 2,224 |
| 0 | 76 | 65 | 52 | 1,311 | 856 | 766 | |
| 151 | 53 | 75 | 107 | 411 | 274 | 600 | |
| Total Liabilities | 434 | 586 | 788 | 988 | 2,880 | 2,919 | 3,606 |
| 36 | 87 | 76 | 59 | 1,833 | 1,790 | 1,863 | |
| CWIP | 0 | 0 | 0 | 0 | 3 | 13 | 2 |
| Investments | 1 | 14 | 16 | 32 | 195 | 114 | 361 |
| 397 | 485 | 695 | 898 | 849 | 1,003 | 1,380 | |
| Total Assets | 434 | 586 | 788 | 988 | 2,880 | 2,919 | 3,606 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 163 | 175 | 233 | 288 | 210 | 318 | |
| -79 | -167 | -82 | -158 | -1,137 | 241 | |
| -41 | -37 | -59 | -152 | 780 | -389 | |
| Net Cash Flow | 43 | -28 | 92 | -22 | -147 | 170 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 51 | 49 | 46 | 57 | 73 | 73 |
| Inventory Days | ||||||
| Days Payable | ||||||
| Cash Conversion Cycle | 51 | 49 | 46 | 57 | 73 | 73 |
| Working Capital Days | 20 | 41 | 15 | 21 | -75 | 10 |
| ROCE % | 47% | 47% | 50% | 30% | 27% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Adjusted EBITDA per employee INR million |
|
|||
| Average Ageing of Top 10 Clients Years |
||||
| Number of Healthcare Organizations / Clients Count |
||||
| Revenue Contribution from Top 10 Customers Percentage |
||||
| Total Employees Count |
||||
| Clinically Trained Staff Count |
||||
| Revenue from Repeat Customers Percentage |
||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
||||
Documents
Announcements
-
Grant Of Employee Stock Options Under Employee Stock Option Plan 2022
1d - Grant of 600,000 ESOPs on March 5, 2026 at Rs.1,331 exercise price.
-
Grant Of Employee Stock Options Under Employee Stock Option Plan 2022
24 Feb - 54,000 ESOPs granted at Rs.1,540.20 each on Feb 24, 2026; convertible to one equity share.
-
Grant Of Employees Stock Options Under Employee Stock Option Plan 2022.
20 Feb - Grant of 75,000 ESOPs at Rs.1,658.40 per option on Feb 20, 2026.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
19 Feb - Read with Schedule III and other applicable provisions of the SEBI (LODR) Regulations, 2015, we hereby inform you of the Schedule of the Analyst / …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
11 Feb - Transcript of the Q3 FY 2025-26 Earnings Conference Call is enclosed.
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
Jul 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
IKSL is a technology-enabled healthcare solutions provider which offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. It partners with an outpatient and inpatient health care organizations, enabling them to deliver superior clinical care through a fee for value model.